Evaluation of Abbreviated Versus Conventional Course of Dabigatran Etexilate Before Electric Cardioversion in Patients With Atrial Fibrillation (RE-SOUND Study)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.
Also called NCT03975062
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 400 participants
- Sponsor
- Registry
-
NCT03975062
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Russia
- Registry status
- Unknown status
Technical summary
Registry record NCT03975062. Randomized; single masking; primary purpose prevention. Start 2017-12-28 (actual); primary completion 2020-12-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of Abbreviated Versus Conventional Course of Dabigatran Etexilate Before Electric Cardioversion in Patients With Atrial Fibrillation (RE-SOUND Study)
- Acronym
- RE-SOUND
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- dabigatran etexilate
- Lead sponsor
- Ural State Medical University
- Collaborator
- Boehringer Ingelheim
Record details
- Record id
cardio:ct-nct03975062- Content hash
f6bb3aaded7a2f92d687dafd4077cf4dcc5ce0c828d3e558de3d4df33f01cc6b